Transatlantic differences in assessment of risk of sudden cardiac death in patients with hypertrophic cardiomyopathy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10295005" target="_blank" >RIV/00216208:11130/15:10295005 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/15:10295005

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.ijcard.2015.03.207" target="_blank" >http://dx.doi.org/10.1016/j.ijcard.2015.03.207</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ijcard.2015.03.207" target="_blank" >10.1016/j.ijcard.2015.03.207</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Transatlantic differences in assessment of risk of sudden cardiac death in patients with hypertrophic cardiomyopathy

Popis výsledku v původním jazyce

We have retrospectively evaluated 133 consecutive HCM patients (48.1 +- 15.8 years, 45% females) diagnosed in our center in whom all potential risk factors according to ACCF/AHA (Table 1) and ESC risk stratifications were available. Patients with ICD implanted in secondary prevention of SCD (Class I) have not been included. Mean duration of follow-up was 5.5 +- 2.2 years (median 5.5 years; range 2-100 months, 677 patient-years). Nine patients (6.8%) underwent ICD implantation according to the National HCM Guidelines [4] during the study period. Five patients (3.8%) died (two of pulmonary carcinoma, two of stroke and one soon after surgery). A total of three patients (2.3%) experienced one appropriate ICD discharge (the annual risk of sudden mortality event was 0.55%). A comparison of risk stratification according to ESC and ACCF/AHA guidelines in these three patients is presented in Table 2.

Název v anglickém jazyce

Transatlantic differences in assessment of risk of sudden cardiac death in patients with hypertrophic cardiomyopathy

Popis výsledku anglicky

We have retrospectively evaluated 133 consecutive HCM patients (48.1 +- 15.8 years, 45% females) diagnosed in our center in whom all potential risk factors according to ACCF/AHA (Table 1) and ESC risk stratifications were available. Patients with ICD implanted in secondary prevention of SCD (Class I) have not been included. Mean duration of follow-up was 5.5 +- 2.2 years (median 5.5 years; range 2-100 months, 677 patient-years). Nine patients (6.8%) underwent ICD implantation according to the National HCM Guidelines [4] during the study period. Five patients (3.8%) died (two of pulmonary carcinoma, two of stroke and one soon after surgery). A total of three patients (2.3%) experienced one appropriate ICD discharge (the annual risk of sudden mortality event was 0.55%). A comparison of risk stratification according to ESC and ACCF/AHA guidelines in these three patients is presented in Table 2.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Cardiology

ISSN

0167-5273

e-ISSN

—

Svazek periodika

186

Číslo periodika v rámci svazku

květen

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

2

Strana od-do

3-4

Kód UT WoS článku

000354337200002

EID výsledku v databázi Scopus

2-s2.0-84929224010